Takeda Pharmaceutical Company Limited announced that it completed the purchase of 395,000 shares of treasury stock (total amount of 1,614,366,000 yen) from August 2025 to May 2026, bringing the total acquired shares to 4,823,900 shares (total amount of 179,999,366,600 yen).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4401","jir_company_name":"Takeda Pharmaceutical Company Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-06-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4401-20260603-01.pdf","jir_short_summary":"Takeda Pharmaceutical Company Limited announced that it completed the purchase of 395,000 shares of treasury stock (total amount of 1,614,366,000 yen) from August 2025 to May 2026, bringing the total acquired shares to 4,823,900 shares (total amount of 179,999,366,600 yen).","jir_summary":"### Overview of Capital Policy\nTakeda Pharmaceutical Company Limited conducted share buybacks from August 2025 to May 2026, acquiring a total of 395,000 shares for approximately 1.61 billion yen through open market purchases. As a result, the total acquired treasury stock reached 4,823,900 shares, and the share repurchase was completed within the acquisition period. The maximum number of shares to be repurchased in August 2025 was 10,000,000 shares (9.8% of issued shares), with the method of purchase being market transactions based on a discretionary trading agreement.\n\n### Impact on Shareholders and Future Outlook\nWith the completion of this share buyback, the company has fulfilled its capital policy aimed at enhancing shareholder value and preventing dilution of shares. Going forward, the company plans to continue shareholder returns and improve capital efficiency, with share cancellation scheduled once the designated date is decided. As part of its capital policy, the company will manage its shares appropriately and aim to maximize shareholder interests.","jir_financial_highlights":"Total number of shares acquired of treasury stock: 4,823,900 shares (Cumulative)\nTotal purchase price: 17,999,936,600 yen (Cumulative)\nAcquisition period: August 12, 2025 \u2013 May 29, 2026 (Implementation period)","jir_category":"","jir_hashtags":"#TakedaPharmaceutical, #ShareBuyback, #JapanStocks","jir_key_figures":"Total shares of treasury stock acquired: 4,823,900 shares\nTotal purchase price: 17,999,936,600 yen\nAcquisition period: August 12, 2025 \u2013 May 29, 2026","jir_meta_title":"\u3010Takeda Pharmaceutical Company Limited\u3011Share Buyback Completed | June 2026","jir_meta_description":"Takeda Pharmaceutical Company Limited announced that it acquired 395,000 shares of treasury stock (approximately 16.1 billion yen) from August 2025 to May 2026, completing the buyback. Enhancing shareholder returns.","jir_og_title":"\u3010Takeda Pharmaceutical\u3011Share Buyback Completed | June 2026","jir_og_description":"Takeda Pharmaceutical announced the completion of its share buyback, having acquired treasury stock from August 2025 to May 2026. Aiming to improve shareholder returns and capital efficiency.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7996,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-56457","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n